Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001, 2 (2): 127-137. 10.1038/35052073.
Article
CAS
PubMed
Google Scholar
Alroy I, Yarden Y: The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett. 1997, 410 (1): 83-86. 10.1016/S0014-5793(97)00412-2.
Article
CAS
PubMed
Google Scholar
Graus-Porta DBR, Daly JM, Hynes NE: ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 1997, 16 (7): 1647-1655. 10.1093/emboj/16.7.1647.
Article
CAS
PubMed
PubMed Central
Google Scholar
Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus-Porta D, Ratzkin BJ, Seger R, Hynes NE, Yarden Y: ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. Embo J. 1996, 15 (2): 254-264.
CAS
PubMed
PubMed Central
Google Scholar
Beerli RR, Graus-Porta D, Woods-Cook K, Chen X, Yarden Y, Hynes NE: Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2. Mol Cell Biol. 1995, 15 (12): 6496-6505.
Article
CAS
PubMed
PubMed Central
Google Scholar
Graus-Porta D, Beerli RR, Hynes NE: Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling. Mol Cell Biol. 1995, 15 (3): 1182-1191.
Article
CAS
PubMed
PubMed Central
Google Scholar
Soltoff SP, Carraway KL, Prigent SA, Gullick WG, Cantley LC: ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol. 1994, 14 (6): 3550-3558.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hellyer NJ, Kim MS, Koland JG: Heregulin-dependent activation of phosphoinositide 3-kinase and Akt via the ErbB2/ErbB3 co-receptor. J Biol Chem. 2001, 276 (45): 42153-42161. 10.1074/jbc.M102079200.
Article
CAS
PubMed
Google Scholar
Confalonieri S, Salcini AE, Puri C, Tacchetti C, Di Fiore PP: Tyrosine phosphorylation of Eps15 is required for ligand-regulated, but not constitutive, endocytosis. J Cell Biol. 2000, 150 (4): 905-912. 10.1083/jcb.150.4.905.
Article
CAS
PubMed
PubMed Central
Google Scholar
Levkowitz G, Klapper LN, Tzahar E, Freywald A, Sela M, Yarden Y: Coupling of the c-Cbl protooncogene product to ErbB-1/EGF-receptor but not to other ErbB proteins. Oncogene. 1996, 12 (5): 1117-1125.
CAS
PubMed
Google Scholar
Sliwkowski MX, Schaefer G, Akita RW, Lofgren JA, Fitzpatrick VD, Nuijens A, Fendly BM, Cerione RA, Vandlen RL, Carraway KL: Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem. 1994, 269 (20): 14661-14665.
CAS
PubMed
Google Scholar
Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M, et al: Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. Embo J. 1996, 15 (10): 2452-2467.
CAS
PubMed
PubMed Central
Google Scholar
Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, Hynes NE: The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA. 2003, 100 (15): 8933-8938. 10.1073/pnas.1537685100.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ross JS, Fletcher JA: The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy. Stem Cells. 1998, 16 (6): 413-428. 10.1002/stem.160413.
Article
CAS
PubMed
Google Scholar
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987, 235 (4785): 177-182. 10.1126/science.3798106.
Article
CAS
PubMed
Google Scholar
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001, 344 (11): 783-792. 10.1056/NEJM200103153441101.
Article
CAS
PubMed
Google Scholar
Menard S, Pupa SM, Campiglio M, Tagliabue E: Biologic and therapeutic role of HER2 in cancer. Oncogene. 2003, 22 (42): 6570-6578. 10.1038/sj.onc.1206779.
Article
CAS
PubMed
Google Scholar
Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004, 304 (5676): 1497-1500. 10.1126/science.1099314.
Article
CAS
PubMed
Google Scholar
El Rayes BF, LoRusso PM: Targeting the epidermal growth factor receptor. Br J Cancer. 2004, 91 (3): 418-10.1038/sj.bjc.6601921.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lin NU, Winer EP: New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors. Breast Cancer Res. 2004, 6 (5): 204-210. 10.1186/bcr919.
Article
CAS
PubMed
PubMed Central
Google Scholar
Jahanzeb M: Adjuvant trastuzumab therapy for HER2-positive breast cancer. Clin Breast Cancer. 2008, 8 (4): 324-333. 10.3816/CBC.2008.n.037.
Article
CAS
PubMed
Google Scholar
Suzuki E, Toi M: Improving the efficacy of trastuzumab in breast cancer. Cancer science. 2007, 98 (6): 767-771. 10.1111/j.1349-7006.2007.00455.x.
Article
CAS
PubMed
Google Scholar
Ahr A, Karn T, Solbach C, Seiter T, Strebhardt K, Holtrich U, Kaufmann M: Identification of high risk breast-cancer patients by gene expression profiling. Lancet. 2002, 359 (9301): 131-132. 10.1016/S0140-6736(02)07337-3.
Article
PubMed
Google Scholar
West M, Blanchette C, Dressman H, Huang E, Ishida S, Spang R, Zuzan H, Olson JA, Marks JR, Nevins JR: Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci USA. 2001, 98 (20): 11462-11467. 10.1073/pnas.201162998.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, Meltzer P, Gusterson B, Esteller M, Kallioniemi OP, et al: Gene-expression profiles in hereditary breast cancer. N Engl J Med. 2001, 344 (8): 539-548. 10.1056/NEJM200102223440801.
Article
CAS
PubMed
Google Scholar
van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002, 415 (6871): 530-536. 10.1038/415530a.
Article
PubMed
Google Scholar
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS. 2001, 98 (19): 10869-10874. 10.1073/pnas.191367098.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003, 100 (14): 8418-8423. 10.1073/pnas.0932692100.
Article
CAS
PubMed
PubMed Central
Google Scholar
Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumours. Nature. 2000, 406 (6797): 747-752. 10.1038/35021093.
Article
CAS
PubMed
Google Scholar
Stamps AC, Davies SC, Burman J, O'Hare MJ: Analysis of proviral integration in human mammary epithelial cell lines immortalized by retroviral infection with a temperature-sensitive SV40 T-antigen construct. Int J Cancer. 1994, 57 (6): 865-874. 10.1002/ijc.2910570616.
Article
CAS
PubMed
Google Scholar
Harris RA, Eichholtz TJ, Hiles ID, Page MJ, O'Hare MJ: New model of ErbB-2 over-expression in human mammary luminal epithelial cells. Int J Cancer. 1999, 80 (3): 477-484. 10.1002/(SICI)1097-0215(19990129)80:3<477::AID-IJC23>3.0.CO;2-W.
Article
CAS
PubMed
Google Scholar
Timms JF, White SL, O'Hare MJ, Waterfield MD: Effects of ErbB-2 overexpression on mitogenic signalling and cell cycle progression in human breast luminal epithelial cells. Oncogene. 2002, 21 (43): 6573-6586. 10.1038/sj.onc.1205847.
Article
CAS
PubMed
Google Scholar
Yang YH, Dudoit S, Luu P, Lin DM, Peng V, Ngai J, Speed TP: Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res. 2002, 30 (4): e15-10.1093/nar/30.4.e15.
Article
PubMed
PubMed Central
Google Scholar
Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA. 2001, 98 (9): 5116-5121. 10.1073/pnas.091062498.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ricort JM: Insulin-like growth factor binding protein (IGFBP) signalling. Growth Horm IGF Res. 2004, 14 (4): 277-286. 10.1016/j.ghir.2004.02.002.
Article
CAS
PubMed
Google Scholar
Helle SI: The insulin-like growth factor system in advanced breast cancer. Best Pract Res Clin Endocrinol Metab. 2004, 18 (1): 67-79. 10.1016/S1521-690X(03)00045-9.
Article
CAS
PubMed
Google Scholar
Mackay A, Jones C, Dexter T, Silva RL, Bulmer K, Jones A, Simpson P, Harris RA, Jat PS, Neville AM, et al: cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells. Oncogene. 2003, 22 (17): 2680-2688. 10.1038/sj.onc.1206349.
Article
CAS
PubMed
Google Scholar
White SL, Gharbi S, Bertani MF, Chan HL, Waterfield MD, Timms JF: Cellular responses to ErbB-2 overexpression in human mammary luminal epithelial cells: comparison of mRNA and protein expression. Br J Cancer. 2004, 90 (1): 173-181. 10.1038/sj.bjc.6601458.
Article
CAS
PubMed
PubMed Central
Google Scholar
Tsai MS, Shamon-Taylor LA, Mehmi I, Tang CK, Lupu R: Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer. Oncogene. 2003, 22 (5): 761-768. 10.1038/sj.onc.1206130.
Article
CAS
PubMed
Google Scholar
Atlas E, Cardillo M, Mehmi I, Zahedkargaran H, Tang C, Lupu R: Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo. Mol Cancer Res. 2003, 1 (3): 165-175.
CAS
PubMed
Google Scholar
Moffatt P, Plaa GL, Denizeau F: Induction of metallothionein gene expression by epidermal growth factor and its inhibition by transforming growth factor-beta and dexamethasone in rat hepatocytes. Hepatology. 1995, 21 (4): 1038-1044.
CAS
PubMed
Google Scholar
Goulding H, Jasani B, Pereira H, Reid A, Galea M, Bell JA, Elston CW, Robertson JF, Blamey RW, Nicholson RA: Metallothionein expression in human breast cancer. Br J Cancer. 1995, 72 (4): 968-
Article
CAS
PubMed
PubMed Central
Google Scholar
Theocharis SE, Margeli AP, Klijanienko JT, Kouraklis GP: Metallothionein expression in human neoplasia. Histopathology. 2004, 45 (2): 103-10.1111/j.1365-2559.2004.01922.x.
Article
CAS
PubMed
Google Scholar
Pelengaris S, Khan M: The many faces of c-MYC. Arch Biochem Biophys. 2003, 416 (2): 129-136. 10.1016/S0003-9861(03)00294-7.
Article
CAS
PubMed
Google Scholar
Cuny M, Kramar A, Courjal F, Johannsdottir V, Iacopetta B, Fontaine H, Grenier J, Culine S, Theillet C: Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. Cancer Res. 2000, 60 (4): 1077-1083.
CAS
PubMed
Google Scholar
Ben-Porath I, Yanuka O, Benvenisty N: The tmp gene, encoding a membrane protein, is a c-Myc target with a tumorigenic activity. Mol Cell Biol. 1999, 19 (5): 3529-3539.
Article
CAS
PubMed
PubMed Central
Google Scholar
Jain A, Tindell CA, Laux I, Hunter JB, Curran J, Galkin A, Afar DE, Aronson N, Shak S, Natale RB, et al: Epithelial membrane protein-1 is a biomarker of gefitinib resistance. Proc Natl Acad Sci USA. 2005, 102 (33): 11858-11863. 10.1073/pnas.0502113102.
Article
CAS
PubMed
PubMed Central
Google Scholar
Xiong S, Grijalva R, Zhang L, Nguyen NT, Pisters PW, Pollock RE, Yu D: Up-regulation of vascular endothelial growth factor in breast cancer cells by the heregulin-beta1-activated p38 signaling pathway enhances endothelial cell migration. Cancer Res. 2001, 61 (4): 1727-1732.
CAS
PubMed
Google Scholar
Yen L, You XL, Al Moustafa AE, Batist G, Hynes NE, Mader S, Meloche S, Alaoui-Jamali MA: Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene. 2000, 19 (31): 3460-3469. 10.1038/sj.onc.1203685.
Article
CAS
PubMed
Google Scholar
Roybal CN, Yang S, Sun CW, Hurtado D, Vander Jagt DL, Townes TM, Abcouwer SF: Homocysteine increases the expression of vascular endothelial growth factor by a mechanism involving endoplasmic reticulum stress and transcription factor ATF4. J Biol Chem. 2004, 279 (15): 14844-14852. 10.1074/jbc.M312948200.
Article
CAS
PubMed
Google Scholar
Zhan Q: Gadd45a, a p53- and BRCA1-regulated stress protein, in cellular response to DNA damage. Mutation research. 2005, 569 (1-2): 133-143.
Article
CAS
PubMed
Google Scholar
Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, Kinzler KW, Vogelstein B: 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell. 1997, 1 (1): 3-11. 10.1016/S1097-2765(00)80002-7.
Article
CAS
PubMed
Google Scholar
Farooq A, Zhou MM: Structure and regulation of MAPK phosphatases. Cell Signal. 2004, 16 (7): 769-779. 10.1016/j.cellsig.2003.12.008.
Article
CAS
PubMed
Google Scholar
Schwartz DC, Hochstrasser M: A superfamily of protein tags: ubiquitin, SUMO and related modifiers. Trends Biochem Sci. 2003, 28 (6): 321-328. 10.1016/S0968-0004(03)00113-0.
Article
CAS
PubMed
Google Scholar
Zhao C, Beaudenon SL, Kelley ML, Waddell MB, Yuan W, Schulman BA, Huibregtse JM, Krug RM: The UbcH8 ubiquitin E2 enzyme is also the E2 enzyme for ISG15, an IFN-alpha/beta-induced ubiquitin-like protein. Proc Natl Acad Sci USA. 2004, 101 (20): 7578-7582. 10.1073/pnas.0402528101.
Article
CAS
PubMed
PubMed Central
Google Scholar
Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD: How cells respond to interferons. Annu Rev Biochem. 1998, 67: 227-264. 10.1146/annurev.biochem.67.1.227.
Article
CAS
PubMed
Google Scholar
Baxter RC: Signalling pathways involved in antiproliferative effects of IGFBP-3: a review. Mol Pathol. 2001, 54 (3): 145-148. 10.1136/mp.54.3.145.
Article
CAS
PubMed
PubMed Central
Google Scholar
Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M: Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science. 1998, 279 (5350): 563-566. 10.1126/science.279.5350.563.
Article
CAS
PubMed
Google Scholar
Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ: Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst. 1999, 91 (7): 620-625. 10.1093/jnci/91.7.620.
Article
CAS
PubMed
Google Scholar
Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X: Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst. 1999, 91 (2): 151-156. 10.1093/jnci/91.2.151.
Article
CAS
PubMed
Google Scholar
Balana ME, Labriola L, Salatino M, Movsichoff F, Peters G, Charreau EH, Elizalde PV: Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells. Oncogene. 2001, 20 (1): 34-47. 10.1038/sj.onc.1204050.
Article
CAS
PubMed
Google Scholar
Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ: Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 2005, 65 (23): 11118-11128. 10.1158/0008-5472.CAN-04-3841.
Article
CAS
PubMed
Google Scholar
Huang X, Gao L, Wang S, McManaman JL, Thor AD, Yang X, Esteva FJ, Liu B: Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin. Cancer Res. 2010, 70 (3): 1204-1214. 10.1158/0008-5472.CAN-09-3321.
Article
CAS
PubMed
Google Scholar
Dar AA, Majid S, Nosrati M, de Semir D, Federman S, Kashani-Sabet M: Functional modulation of IGF-binding protein-3 expression in melanoma. J Invest Dermatol. 2010, 130 (8): 2071-2079. 10.1038/jid.2010.70.
Article
CAS
PubMed
PubMed Central
Google Scholar
Torng PL, Lin CW, Chan MW, Yang HW, Huang SC, Lin CT: Promoter methylation of IGFBP-3 and p53 expression in ovarian endometrioid carcinoma. Molecular cancer. 2009, 8: 120-10.1186/1476-4598-8-120.
Article
PubMed
PubMed Central
Google Scholar
Takaoka M, Smith CE, Mashiba MK, Okawa T, Andl CD, El-Deiry WS, Nakagawa H: EGF-mediated regulation of IGFBP-3 determines esophageal epithelial cellular response to IGF-I. American journal of physiology. 2006, 290 (2): G404-416.
CAS
PubMed
Google Scholar
Yamada PM, Lee KW: Perspectives in mammalian IGFBP-3 biology: local vs. systemic action. Am J Physiol Cell Physiol. 2009, 296 (5): C954-976. 10.1152/ajpcell.00598.2008.
Article
CAS
PubMed
Google Scholar
Perks CM, Holly JM: IGF binding proteins (IGFBPs) and regulation of breast cancer biology. J Mammary Gland Biol Neoplasia. 2008, 13 (4): 455-469. 10.1007/s10911-008-9106-4.
Article
PubMed
Google Scholar
Stull MA, Richert MM, Loladze AV, Wood TL: Requirement for IGF-I in epidermal growth factor-mediated cell cycle progression of mammary epithelial cells. Endocrinology. 2002, 143 (5): 1872-1879. 10.1210/en.143.5.1872.
Article
CAS
PubMed
Google Scholar
Martin JL, Weenink SM, Baxter RC: Insulin-like Growth Factor-binding Protein-3 Potentiates Epidermal Growth Factor Action in MCF-10A Mammary Epithelial Cells. INVOLVEMENT OF p44/42 AND p38 MITOGEN-ACTIVATED PROTEIN KINASES. JBiolChem. 2003, 278 (5): 2969-
CAS
Google Scholar
Butt AJ, Martin JL, Dickson KA, McDougall F, Firth SM, Baxter RC: Insulin-like growth factor binding protein-3 expression is associated with growth stimulation of T47D human breast cancer cells: the role of altered epidermal growth factor signaling. J Clin EndocrinolMetab. 2004, 89 (4): 1950-10.1210/jc.2003-030914.
Article
CAS
Google Scholar
Chan HL, Gharbi S, Gaffney PR, Cramer R, Waterfield MD, Timms JF: Proteomic analysis of redox- and ErbB2-dependent changes in mammary luminal epithelial cells using cysteine- and lysine-labelling two-dimensional difference gel electrophoresis. Proteomics. 2005, 5 (11): 2908-2926. 10.1002/pmic.200401300.
Article
CAS
PubMed
Google Scholar
Han B, Nakamura M, Mori I, Nakamura Y, Kakudo K: Urokinase-type plasminogen activator system and breast cancer (Review). Oncol Rep. 2005, 14 (1): 105-112.
CAS
PubMed
Google Scholar
Andreasen PA, Egelund R, Petersen HH: The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci. 2000, 57 (1): 25-40. 10.1007/s000180050497.
Article
CAS
PubMed
Google Scholar
Liu D, Rudland PS, Sibson DR, Platt-Higgins A, Barraclough R: Human homologue of cement gland protein, a novel metastasis inducer associated with breast carcinomas. Cancer Res. 2005, 65 (9): 3796-3805. 10.1158/0008-5472.CAN-04-3823.
Article
CAS
PubMed
Google Scholar
Lin CS, Chen ZP, Park T, Ghosh K, Leavitt J: Characterization of the human L-plastin gene promoter in normal and neoplastic cells. J Biol Chem. 1993, 268 (4): 2793-2801.
CAS
PubMed
Google Scholar
Guerreiro Da Silva ID, Hu YF, Russo IH, Ao X, Salicioni AM, Yang X, Russo J: S100P calcium-binding protein overexpression is associated with immortalization of human breast epithelial cells in vitro and early stages of breast cancer development in vivo. Int J Oncol. 2000, 16 (2): 231-240.
CAS
PubMed
Google Scholar
Gharbi S, Gaffney P, Yang A, Zvelebil MJ, Cramer R, Waterfield MD, Timms JF: Evaluation of two-dimensional differential gel electrophoresis for proteomic expression analysis of a model breast cancer cell system. Mol Cell Proteomics. 2002, 1 (2): 91-98. 10.1074/mcp.T100007-MCP200.
Article
CAS
PubMed
Google Scholar